company background image
CTLT logo

Catalent NYSE:CTLT Stock Report

Last Price

US$63.48

Market Cap

US$11.5b

7D

2.0%

1Y

42.2%

Updated

17 Dec, 2024

Data

Company Financials +

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

CTLT Stock Overview

Develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. More details

CTLT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Catalent, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Catalent
Historical stock prices
Current Share PriceUS$63.48
52 Week HighUS$63.50
52 Week LowUS$42.07
Beta1.14
1 Month Change7.41%
3 Month Change5.24%
1 Year Change42.20%
3 Year Change-49.02%
5 Year Change13.32%
Change since IPO217.56%

Recent News & Updates

Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Aug 30
Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Recent updates

Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Aug 30
Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Jul 23
Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Jun 25

Catalent - Novo Holdings Merger: Attractive Spread

Feb 07

Catalent: Debt Remains An Overhang

Dec 13

Catalent Remains Overvalued

Oct 04

Catalent: Myriad Issues To Fix

Jul 31

Why did Catalent stock soar today? Potential takeover by Danaher

Feb 06

Shareholder Returns

CTLTUS PharmaceuticalsUS Market
7D2.0%-0.3%-2.7%
1Y42.2%7.9%23.4%

Return vs Industry: CTLT exceeded the US Pharmaceuticals industry which returned 9.1% over the past year.

Return vs Market: CTLT exceeded the US Market which returned 27.3% over the past year.

Price Volatility

Is CTLT's price volatile compared to industry and market?
CTLT volatility
CTLT Average Weekly Movement1.4%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: CTLT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: CTLT's weekly volatility (1%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
193316,900Alessandro Maselliwww.catalent.com

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Catalent, Inc. Fundamentals Summary

How do Catalent's earnings and revenue compare to its market cap?
CTLT fundamental statistics
Market capUS$11.52b
Earnings (TTM)-US$413.00m
Revenue (TTM)US$4.42b

2.6x

P/S Ratio

-27.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTLT income statement (TTM)
RevenueUS$4.42b
Cost of RevenueUS$3.46b
Gross ProfitUS$965.00m
Other ExpensesUS$1.38b
Earnings-US$413.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.28
Gross Margin21.82%
Net Profit Margin-9.34%
Debt/Equity Ratio130.0%

How did CTLT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/17 10:13
End of Day Share Price 2024/12/17 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Catalent, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Sel HardyCFRA Equity Research
Parth TalsaniaEquisights